Ivabradine Zentiva

Ivabradine, the active ingredient in Ivabradine Zentiva, is a If channel inhibitor presented as an oral tablet for oral use. It treats chronic stable angina and heart failure in appropriate adult patients by lowering heart rate without affecting myocardial contractility.

GNH USA supplies Ivabradine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine Zentiva is an If channel inhibitor indicated for conditions where heart‑rate reduction improves outcomes.

- Chronic stable angina: decreases the frequency of angina attacks by lowering resting heart rate. - Heart failure with reduced ejection fraction: improves exercise capacity and reduces hospitalization risk when added to standard therapy. - Symptomatic sinus tachycardia: controls excessive heart rate when other measures are insufficient.

Adverse reactions may be observed with Ivabradine therapy.

Common Side Effects: - Bradycardia: resting heart rate below 50 bpm. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other supraventricular arrhythmias. - Severe hypotension leading to syncope. - Heart block (second‑ or third‑degree).

When prescribing Ivabradine, clinicians should consider several safety measures.

- Monitor heart rate: confirm resting heart rate ≥ 60 bpm before initiation. - Assess for concomitant bradycardic agents: adjust doses or discontinue as needed. - Evaluate for severe hepatic impairment: use with caution. - Review electrolyte status: correct abnormalities that may predispose to arrhythmia. - Counsel patients on visual symptoms: advise to report persistent or worsening disturbances. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Ivabradine may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Other heart‑rate‑lowering agents (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive bradycardia. - Certain antiarrhythmics (amiodarone, quinidine): can potentiate bradycardic effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampicin, carbamazepine): may reduce efficacy. - Diuretics and antihypertensives: monitor blood pressure and volume status. - Antidepressants with serotonergic activity: observe for rare visual disturbances. - Herbal supplements (St. John’s wort): possible reduction in drug exposure.